


STATUS OF THE CLAIMS

1-23. (Canceled).

24. (Currently Amended) A method for treating inflammation in a mammal in need thereof which comprises administering an imidazoline ester of the formula:



wherein R1, R2, R3 and R4 are selected from the group consisting of aryl, arylalkyl, heteroaryl containing 5 to 14 ring members, and heterocyclic containing 5 to 12 ring members; and R5 is a alkyl ~~group which provides the ester~~, all of which are optionally substituted, to the mammal in an amount sufficient to inhibit the inflammation.

25. (Original) The method of claim 24 wherein the mammal is human.

26. (Presently Amended) The method of claim 24 wherein the mammal is a ~~lower~~ non-human mammal.

27. (Presently Amended) The method of ~~any one of claims 24, 23 or~~ claim 24 wherein the administration is orally to the mammal.

28. (Original) The method of any one of claims 24, 25 or 26 wherein the administration is topically to the mammal.

29. (Original) The method of any one of claims 24, 25 or 26 wherein the administration is by injection into the mammal.

30. (Original) The method of any one of claims 24, 25 or 26 wherein the administration

is intravenous into the mammal.

31-90 (Canceled)

A method for treating inflammation in a mammal in need thereof which comprises administering an imidazoline ester of the formula:

91. (Presently Amended) The A method for treating inflammation in a mammal in need thereof, said method comprising administering to said mammal an imidazoline of Claim 24, wherein said imidazoline ester is

